KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Gross Profit: 2009-2024

Historic Gross Profit for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $3.6 billion.

  • Jazz Pharmaceuticals' Gross Profit rose 5.71% to $997.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 3.50%. This contributed to the annual value of $3.6 billion for FY2024, which is 6.61% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Gross Profit of $3.6 billion as of FY2024, which was up 6.61% from $3.4 billion recorded in FY2023.
  • In the past 5 years, Jazz Pharmaceuticals' Gross Profit registered a high of $3.6 billion during FY2024, and its lowest value of $2.2 billion during FY2020.
  • For the 3-year period, Jazz Pharmaceuticals' Gross Profit averaged around $3.4 billion, with its median value being $3.4 billion (2023).
  • Data for Jazz Pharmaceuticals' Gross Profit shows a peak YoY climbed of 19.81% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Jazz Pharmaceuticals' Gross Profit stood at $2.2 billion in 2020, then rose by 19.81% to $2.7 billion in 2021, then grew by 17.54% to $3.1 billion in 2022, then rose by 8.97% to $3.4 billion in 2023, then rose by 6.61% to $3.6 billion in 2024.